Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03521154 · OUTCOME

Duration of Response, Unconfirmed by Blinded Independent Central Review (BICR)

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) · Source last updated 2026-08-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
Inter-Quartile Range
Time frame
Every 8 weeks for first 48 weeks, then every 12 weeks until radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months

What was measured

Date of PFS event - date of first unconfirmed response + 1 day (and expressed in months) for unconfirmed responses only

Analysis population: Full analysis set

Groups in this outcome

Osimertinib

80mg once daily tablet

Placebo

Matching Placebo

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Osimertinib82
Placebo24

Reported measurements

Source class 1
Values in Months · Interval/dispersion: Inter-Quartile Range
GroupValueSpreadLowerUpperComment
Osimertinib36.9Not reported17.9NANA - Not calculated as insufficient number of events to enable 75% percentile to be calculated
Placebo6.5Not reported3.29.0Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        NA - Not calculated as insufficient number of events to enable 75% percentile to be calculated
        group Id
        OG000
        lower Limit
        17.9
        upper Limit
        NA
        value
        36.9
      2. group Id
        OG001
        lower Limit
        3.2
        upper Limit
        9.0
        value
        6.5
denoms
  1. counts
    1. group Id
      OG000
      value
      82
    2. group Id
      OG001
      value
      24
    units
    Participants
description
Date of PFS event - date of first unconfirmed response + 1 day (and expressed in months) for unconfirmed responses only
dispersion Type
Inter-Quartile Range
groups
  1. description
    80mg once daily tablet
    id
    OG000
    title
    Osimertinib
  2. description
    Matching Placebo
    id
    OG001
    title
    Placebo
param Type
MEDIAN
population Description
Full analysis set
reporting Status
POSTED
time Frame
Every 8 weeks for first 48 weeks, then every 12 weeks until radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
title
Duration of Response, Unconfirmed by Blinded Independent Central Review (BICR)
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice